文献速递癫痫认知障碍与痴呆

结节性硬化症遗传学与神经病理学进展:更接近靶向治疗

Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy.
PubMed 文献 · Lancet Neurol · 2022-01-01

结节性硬化症由TSC1或TSC2基因突变引起mTOR复合物过度激活。近5年对基因变异细胞后果及mTORC1过度激活在神经元和胶质细胞中的作用认识加深。1-5岁婴幼儿或可从基因变异状态和嵌合体早期评估中获益,EEG和MRI生物标志物可在更早年龄识别癫痫、自闭症和发育迟缓风险,氨己烯酸成功用于EEG异常但未发作的婴儿,mTOR抑制剂西罗莫司和依维莫司等拓宽了症状缓解范围。

要点

  • 1-5岁结节性硬化症婴幼儿或可从基因变异状态和嵌合体早期评估中获益。
  • 可靠EEG和MRI生物标志物可在更早年龄识别癫痫、自闭症和发育迟缓风险婴儿。
  • 氨己烯酸成功用于EEG异常但未发作的结节性硬化症婴儿。

核心结论

  • 近5年对TSC1和TSC2基因变异细胞后果及mTORC1过度激活在神经元和胶质细胞中作用的认识加深,许多潜在疾病修饰策略已被识别。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 过去5年对mTOR相关神经病理及癫痫发生和共病神经发育障碍分子方面的理解取得实质进展。
  • 可靠EEG和MRI生物标志物可在比以前更早年龄识别有癫痫、自闭症和发育迟缓风险的结节性硬化症婴儿。
  • 氨己烯酸已成功用于EEG异常但尚未发作的结节性硬化症婴儿。

关键数值与推荐

  • 原文未报告具体标准或数值。

临床怎么用

  • 1-5岁结节性硬化症婴幼儿或可从基因变异状态和嵌合体早期评估中获益。
  • 基于分子发现的靶向治疗在癫痫中取得进展,mTOR抑制剂西罗莫司和依维莫司等用于缓解结节性硬化症相关症状。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberous sclerosis complex is a rare genetic disease associated with mutations in the TSC1 or TSC2 genes, which cause overactivation of the mTOR complex. In the past 5 years, understanding has increased of the cellular consequences of TSC1 and TSC2 genetic variants and the mTORC1 overactivation in neurons and glial cells and their contribution to network dysfunction. Infants and young children (aged 1-5 years) with tuberous sclerosis complex might now benefit from early assessment of gene variant status and mosaicism. In the past 5 years, substantial advances have also been made in our understanding of mTOR-related neuropathology and the molecular aspects of both epileptogenesis and co-occurring neurodevelopmental disorders. Many potential disease-modifying strategies have been identified, including developments in targeted therapies based on molecular findings in epilepsy. Reliable EEG and MRI biomarkers are now available to identify, at a younger age than previously possible, infants with tuberous sclerosis complex who are at risk of epilepsy, autism, and developmental delay. Vigabatrin has been used successfully as a treatment in infants with tuberous sclerosis complex who showed abnormalities on EEG before seizure onset. The scope for mitigation of tuberous sclerosis complex-associated symptoms has expanded, including the use of mTOR inhibitors such as sirolimus and everolimus. Close cooperation between clinical and basic neuroscientists has provided new opportunities for future advances.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Curatolo P, Specchio N, Aronica E, et al. Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. Lancet Neurol. 2022. PMID: 35963265. doi:10.1016/S1474-4422(22)00213-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。